Severine Alran

Summary

Affiliation: Institut Curie
Country: France

Publications

  1. ncbi request reprint Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy
    Severine Alran
    Department of Surgical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Ann Surg Oncol 14:2195-201. 2007
  2. pmc Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
    Anne Marszalek
    Department of Surgery, Institut Curie, 25 rue d Ulm, 75005 Paris, France
    Int J Surg Oncol 2010:214919. 2010
  3. pmc Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 8:e55901. 2013
  4. pmc The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 6:e20297. 2011
  5. doi request reprint High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Breast 21:380-3. 2012
  6. doi request reprint Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer
    Christophe Le Tourneau
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Clin Oncol 35:242-6. 2012
  7. pmc A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
    Jean Philippe Meyniel
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, 75248 Paris, Cedex 05, France
    BMC Cancer 10:222. 2010
  8. pmc Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
    Maura Campitelli
    Department of Radiation Oncology, Institut Curie, Hospital, Paris, France
    PLoS ONE 7:e43393. 2012
  9. doi request reprint Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome
    Pascale This
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248, Paris Cedex 05, France
    Fam Cancer 11:473-82. 2012
  10. doi request reprint Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, 75005 Paris Cedex, France
    Eur J Cancer 45:1979-86. 2009

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy
    Severine Alran
    Department of Surgical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Ann Surg Oncol 14:2195-201. 2007
    ..The purpose of this study was to test the accuracy of the nomogram on patients with macrometastatic and micrometastatic SLN-positive biopsy findings...
  2. pmc Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
    Anne Marszalek
    Department of Surgery, Institut Curie, 25 rue d Ulm, 75005 Paris, France
    Int J Surg Oncol 2010:214919. 2010
    ..The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity of the surgical procedure is discussed...
  3. pmc Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 8:e55901. 2013
    ..The present study aims to validate Ki67 as prognostic factor in a large cohort of early-stage (pT1-pT2, pN0) breast cancer patients...
  4. pmc The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 6:e20297. 2011
    ..The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy...
  5. doi request reprint High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Breast 21:380-3. 2012
    ..Our aim was to evaluate the risk of relapse for lobular carcinoma in situ (LCIS) patients, diagnosed on mammography performed for microcalcifications and according to proliferation assessed by Ki67 staining...
  6. doi request reprint Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer
    Christophe Le Tourneau
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Clin Oncol 35:242-6. 2012
    ....
  7. pmc A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
    Jean Philippe Meyniel
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, 75248 Paris, Cedex 05, France
    BMC Cancer 10:222. 2010
    ..The purpose of the present work was to develop genomic and transcriptomic tools to further refine the pathological diagnosis of ovarian tumors after a previous history of breast cancer...
  8. pmc Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
    Maura Campitelli
    Department of Radiation Oncology, Institut Curie, Hospital, Paris, France
    PLoS ONE 7:e43393. 2012
    ..To determine whether the sequence of the cell-viral junction could be used in clinical practice as a specific marker of ctDNA, we analyzed a series of cervical cancer patient serums...
  9. doi request reprint Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome
    Pascale This
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248, Paris Cedex 05, France
    Fam Cancer 11:473-82. 2012
    ..However, good compliance with prophylactic salpingo-oophorectomy was observed. This study confirms the high breast cancer risk in these women...
  10. doi request reprint Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, 75005 Paris Cedex, France
    Eur J Cancer 45:1979-86. 2009
    ....
  11. doi request reprint Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype
    Patricia De Cremoux
    Department of Tumour Biology, Institut Curie, Paris, France
    Int J Cancer 124:778-82. 2009
    ..One third of invasive carcinoma were not associated with HPV 16/18, indicating that the screening for cervical neoplasia should be maintained after prophylactic vaccination against these HPV genotypes...
  12. pmc Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France Laboratory of Circulating Cancer Biomarker, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Int J Breast Cancer 2013:130470. 2013
    ..We confirm that the detection of CTC is independently associated with a significantly worse outcome, but mainly during the first 3-4 years of follow-up. No prognostic impact is seen in patients who are still relapse-free at this moment...